uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success.

The most dramatic call belongs to uniQure. RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is “not inconceivable” that the FDA reverts to its prior stance, and believes Prasad’s departure is likely to open up a more balanced discussion on risk/reward for Huntington’s disease. RBC now places a 50% chance the drug ultimately gets approved.

The clinical data underpinning that view is meaningful. AMT-130’s Phase I/II 36-month data showed statistically significant 75% slowing in disease progression on cUHDRS (p=0.003) and 60% slowing on TFC (p=0.033). The FDA’s January 2026 directive requires a full randomized, double-blind, sham surgery-controlled Phase III trial before any marketing application, and uniQure has a Type B meeting with the FDA planned for Q2 2026 to discuss Phase III study design.

The stock currently trades at $16.52, well below both price targets. The consensus analyst target sits at $28.45, with 10 buy ratings and 3 holds across the coverage universe. The stock has surged 53.33% over the past week as the upgrade cycle took hold, though it remains down 32.72% year-to-date from its January levels. The binary nature of an FDA outcome remains a key consideration. uniQure does hold $622.5M in cash with runway into H2 2029, limiting near-term dilution risk.

JPMorgan’s call on Syndax is more straightforward. The firm raised its price target to $45 from $33 and kept an Overweight rating. The core argument: at current share levels, no value is being ascribed to the Niktimvo IPF opportunity, with Phase 2 MAXPIRe data expected in Q4 2026. JPMorgan sees the value of Revuforj and Niktimvo in the refractory commercial setting alone in the high-$20s to low-$30s per share range.

Syndax trades at $23.23 against a consensus target of $38.09, with 12 buy ratings and zero sells across coverage. The commercial trajectory supports the bullish read: Revuforj posted Q4 net revenue of $44.20M, up 38% sequentially, with total prescriptions of approximately 1,150, up 35% quarter-over-quarter. Management has guided toward profitability without additional capital raises, adding credibility to the JPMorgan thesis.

JPMorgan added Erasca to its “Positive Catalyst Watch list” ahead of the initial Phase 1 AURORAS-1 readout for ERAS-0015 in RAS-mutant solid tumors, expected in the first half of 2026. The firm sees a high probability of an upside scenario and “multiple ways to win” in the initial update, with share upside into the high-teens to high-$20s in win scenarios. JPMorgan keeps an Overweight rating and established a year-end 2026 price target of $24.

Erasca trades at $15.20, already up 305.17% year-to-date. The stock has moved sharply ahead of the readout, compressing some of the upside implied by JPMorgan’s $24 target. The consensus target of $11.56 sits below the current price, though that figure likely reflects stale ratings predating the recent run. ERAS-0015 carries a U.S. composition of matter patent through September 2043, providing long-duration IP protection if the asset proves out clinically.

Across all three names, the analyst signal is directionally consistent: the market is underpricing catalyst optionality. Each name carries meaningful binary risk tied to upcoming clinical and regulatory readouts.